LATIN AMERICA

We entered the Latin American market in 2008 and initially established a presence in Brazil, Mexico and Venezuela. We have expanded our coverage in this region and now also have a presence in Colombia, Chile, Ecuador, Costa Rica, Peru and Argentina and offer a comprehensive product range that encompasses branded prescription and OTC products as well as infant nutritionals.Our Vallejo site in Mexico has the capability to manufacture infant nutritionals as well as pharmaceutical solids, semisolids and liquids.

Key Countries

Brazil
Chile
Colombia
Ecuador
Mexico

Contribution to Group revenue

Revenue contribution - by therapeutic category

The Spanish Latin American private pharmaceutical sector grew 8,9% to USD25,2 billion for the year to 30 June 2018 as per IMS.
The Brazilian private pharmaceutical sector grew 5,4% and was valued by IMS at USD30,0 billion for the year to 30 June 2018.

Source: June 2018 IMS

STATISTICS

Number of products launched:

11

(2017: 26)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:

0 – 2 years

USD424 million

3 – 5 years

USD298 million

Number of product recalls:

2

(2017: 1)

Average staff turnover:

22,8%

(2017: 29,5%)

Number of work-related fatalities:

Nil

(2017: nil)

Number of permanent employees:

Revenue – R’billion	2018	2017 (CER)	% change
Total	4 231	3 991	6
Commercial Pharmaceuticals	2 929	2 577	14
Regional Brands	1 306	1 116	17
Anaesthetics	762	571	33
Thrombosis	71	87	(18)
High Potency & Cytotoxics	790	803	(2)
Nutritionals	1 290	1 414	(9)
Manufacturing – FDF	12	–	100

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture